Search documented disagreements and product cautions across the local library. Compare complete source versions on the drug page before choosing a regimen.
Search medication names and documented issues only. Do not enter patient information. This directory submits search filters to the server; the within-drug text finder remains a separate local feature.
A difference is not always a contradiction
Compare indication, formulation, route, population, renal method, dialysis conditions and source date. A safety update or source-quality failure is not an alternative dose. These notes are not independent clinical approval, and sources are not ranked or averaged.
451 matching notes. Showing 401-416; page 26 of 29.
The source uses PAH-specific daily instructions and leaves an exact boundary unstated in its numeric dosage bands.
What to reconcile
Do not insert an ED schedule or silently interpolate the boundary. Obtain product-specific clarification.
2 source identities and dates
GlobalRPh RX List - TADLIQ
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. TADLIQ oral suspension for WHO Group 1 pulmonary arterial hypertension; not as-needed erectile dysfunction or a fixed-combination tadalafil product.
DailyMed / CMP Pharma, Inc. | Source revision: 10/2022 TADLIQ oral suspension for WHO Group 1 pulmonary arterial hypertension; not as-needed erectile dysfunction or a fixed-combination tadalafil product.
The RX mirror and exact official label differ for moderate-renal mCRPC dosing with enzalutamide. The disputed mirror extract is documentation, not permission.
What to reconcile
Read the newly dated official section and have oncology/pharmacy adjudicate the discrepancy. Do not average doses or confuse breast-cancer and mCRPC regimens.
2 source identities and dates
GlobalRPh RX List - TALZENNA
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. TALZENNA capsules: separate gBRCAm HER2-negative advanced/metastatic breast-cancer dosing and HRR gene-mutated mCRPC dosing with enzalutamide.
The moderate-renal mCRPC dose disagreement is still present
The current official label states 0.35 mg daily with enzalutamide at CrCl 30-59; the retrieved RX mirror still states 0.5 mg daily for that setting. Breast-cancer monotherapy is a separate regimen.
What to reconcile
Keep the conflict flagged and prioritize the exact official product label; do not average the doses or transfer the monotherapy schedule.
2 source identities and dates
GlobalRPh RX List - TALZENNA
GlobalRPh-hosted RX List | Source revision: 2/2024 (printed mirror revision) TALZENNA: distinguish breast-cancer monotherapy from HRR-mutated mCRPC with enzalutamide.
NUCYNTA: immediate-release evidence is not the ER regimen
The retrieved body describes immediate-release tablets. Unchanged parent-drug PK does not cancel the severe-impairment restriction linked to metabolite accumulation.
What to reconcile
Confirm release form and do not import the failed ER follow-up as verified clinical content.
1 source identities and dates
GlobalRPh RX List - NUCYNTA tablets
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. Tapentadol - NUCYNTA immediate-release tablets; selected source sections, not a full prescribing monograph.
IMDELLTRA: official pharmacokinetics do not repair the partial RX page
The official selected section supplies renal pharmacokinetics, not a stand-alone dosing algorithm for severe impairment or dialysis. The RX rendering remains incomplete.
What to reconcile
Do not convert unchanged pharmacokinetics into an unrestricted no-adjustment recommendation; clarify the source eGFR units.
1 source identities and dates
Tarlatamab-dlle - IMDELLTRA
DailyMed / Amgen Inc. | Source revision: Prescribing information revised 11/2025. IMDELLTRA intravenous tarlatamab-dlle kit; selected pharmacokinetic renal information only, not a step-up dosing or toxicity-management protocol.
The label and mirror specify catheter-lumen use and aspiration/discard before the next HD session.
What to reconcile
Use the catheter-specific volume and workflow. Do not turn failed aspiration guidance into permission for routine systemic flushing.
2 source identities and dates
GlobalRPh RX List - DEFENCATH
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. Antimicrobial catheter lock for adults with kidney failure receiving chronic HD through a central venous catheter; not systemic heparin, systemic anti-infective therapy or a flush product.
DailyMed / CorMedix Inc. | Source revision: 12/2024 Antimicrobial catheter lock for adults with kidney failure receiving chronic HD through a central venous catheter; not systemic heparin, systemic anti-infective therapy or a flush product.
Check IV eligibility before reading no-adjustment wording
The injection has a severe-renal contraindication even though the oral product has a broader no-adjustment statement.
What to reconcile
Keep excipient precautions, monitoring and the IV cutoff attached.
2 source identities and dates
GlobalRPh RX List - TPOXX injection
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. TPOXX injection for labeled human smallpox treatment in patients weighing at least 3 kg; not an oral-capsule or mpox treatment protocol.
DailyMed / SIGA Technologies, Inc. | Source revision: 4/2024 TPOXX injection for labeled human smallpox treatment in patients weighing at least 3 kg; not an oral-capsule or mpox treatment protocol.
The capsule and injection renal statements are different because the injection has an additional excipient-related restriction.
What to reconcile
Confirm route and labeled indication before applying the source.
2 source identities and dates
GlobalRPh RX List - TPOXX capsules
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. TPOXX oral capsules for labeled human smallpox treatment; the oral weight-based schedule starts at 13 kg. This is not an mpox efficacy or eligibility recommendation.
DailyMed / SIGA Technologies, Inc. | Source revision: 4/2024 TPOXX oral capsules for labeled human smallpox treatment; the oral weight-based schedule starts at 13 kg. This is not an mpox efficacy or eligibility recommendation.
Historical no-adjustment wording contains important study gaps
The source no-adjustment statement coexists with limited infected-patient renal data and unstudied ESRD/HD. Its partner-drug requirements are separate.
What to reconcile
Do not use this historical source as a current HCV treatment recommendation or as proof of safety of the full combination in kidney failure.
1 source identities and dates
GlobalRPh RX List - INCIVEK
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. Historical telaprevir combination-treatment source; not a statement of current HCV standard therapy or availability.
Adult HBV dialysis guidance does not supply pediatric renal doses
VEMLIDY has adult chronic-HD instructions, yet the same source explicitly lacks data for renal dose recommendations in pediatric patients. Its broader pediatric indication does not close that renal evidence gap.
What to reconcile
Keep adult and pediatric eligibility separate; verify HBV single-agent product versus HIV combinations, renal function and monitoring. Do not derive a pediatric dialysis schedule from the adult tablet instruction.
1 source identities and dates
GlobalRPh RX List - Vemlidy
GlobalRPh-hosted RX List | Source revision: March 2024 VEMLIDY for chronic hepatitis B; adult renal guidance, not an HIV combination-product schedule.
A response-guided HRS pathway needs eligibility and respiratory review
The official source supplies a complete response pathway absent from the selected RX text rendering. This is not a stable-CKD adjustment table.
What to reconcile
Review oxygenation, volume status, ACLF grade and stopping rules before applying the pathway.
2 source identities and dates
GlobalRPh RX List - TERLIVAZ
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. TERLIVAZ terlipressin IV injection in adults with hepatorenal syndrome and rapid kidney-function reduction. This is a response-guided HRS regimen, not a stable-CKD CrCl table.
DailyMed / Mallinckrodt Hospital Products Inc. | Source revision: 6/2026 TERLIVAZ terlipressin IV injection in adults with hepatorenal syndrome and rapid kidney-function reduction. This is a response-guided HRS regimen, not a stable-CKD CrCl table.
An adult renal statement cannot be extended to neonates
The source distinguishes adult and older-child renal handling from neonatal elimination. Its neonatal warning is not a neonatal extended-release-tablet protocol.
What to reconcile
Confirm age and formulation, and use therapeutic concentration monitoring with other clearance-changing conditions. No renal adjustment does not mean no monitoring.
1 source identities and dates
GlobalRPh RX List - Uniphyl
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. UNIPHYL oral ER product; adult renal statement with explicit neonatal limitation.
Use the monograph formulation, not inconsistent index wording
The body and dosage-form sections distinguish release types despite inconsistent index labels. Renal guidance emphasizes urinary targets and toxicity monitoring.
What to reconcile
Keep release identity and the proteinuria stop/monitor instruction together.
1 source identities and dates
GlobalRPh RX List - THIOLA EC
GlobalRPh-hosted RX List | Source revision: 3/2021 THIOLA EC delayed-release 100 mg and 300 mg tablets for severe homozygous cystinuria in adults and pediatric patients at least 20 kg, with adjunctive measures.
Use the monograph formulation, not inconsistent index wording
The body and dosage-form sections distinguish release types despite inconsistent index labels. Renal guidance emphasizes urinary targets and toxicity monitoring.
What to reconcile
Keep release identity and the proteinuria stop/monitor instruction together.
1 source identities and dates
GlobalRPh RX List - THIOLA
GlobalRPh-hosted RX List | Source revision: 1/2021 THIOLA immediate-release 100 mg tablets for severe homozygous cystinuria in adults and pediatric patients at least 20 kg, with adjunctive measures.
Only documented issues are searchable here. Absence of a note is not agreement. A label mirror and the original label are not independent corroboration, and a source's retrieval date is not its revision date.